Status:

COMPLETED

Evaluation of Combined Action Between Natrecor and Furosemide on Kidney and Neurohormone Responses in Chronic Heart Failure: A Phase-IV study704.351 / DSS

Lead Sponsor:

Scios, Inc.

Conditions:

Congestive Heart Failure

Chronic Heart Failure

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This is a randomized, open-label, three-way crossover design study with 3 treatment groups:TREATMENT A: Furosemide;TREATMENT B: Nesiritide administered IV bolus, followed by an infusion for 6 hours;TR...

Detailed Description

Nesiritide is the recombinant form of human B-type natriuretic peptide (hBNP). The drug is indicated for the IV treatment of patients with acutely decompensated congestive heart failure who have short...

Eligibility Criteria

Inclusion

  • Chronic symptomatic NYHA Class II or III CHF for at least 90 days before the study
  • Left ventricular systolic dysfunction as evidenced by left ventricular ejection fraction \< 40%, measured using contrast or radionuclide ventriculography or by echocardiography, within 180 days of the study start
  • Serum potassium \> 3.5 mEq/L.
  • Chronic oral daily requirement of 80-240 mg of furosemide for at least 7 days before the study start
  • Receiving a stable medical regimen for CHF for at least 60 days before the study start, including angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARBs), and/or beta-blockers.

Exclusion

  • Clinical instability such that withholding diuretic therapy would be unsafe
  • Significant renal impairment (e.g., creatinine clearance \< 45 mL/min by the Cockcroft-Gault formula), or changing renal function during the 7 days before study start, or intrinsic renal disease
  • Systolic blood pressure (SBP) consistently \< 90 mm Hg
  • Myocardial infarction within 90 days of study start, unstable angina within 14 days of study start, or any clinical evidence of active myocardial ischemia
  • Percutaneous coronary intervention or cardiac surgery within 90 days of study start
  • Restrictive or obstructive cardiomyopathy, constrictive pericarditis, pericardial tamponade, other conditions in which cardiac output was dependent on venous return, or for subjects expected to have low filling pressures
  • Prior cardiac or renal allografts

Key Trial Info

Start Date :

March 1 2003

Trial Type :

INTERVENTIONAL

End Date :

January 1 2004

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00652652

Start Date

March 1 2003

End Date

January 1 2004

Last Update

May 19 2011

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.